title: [Intracameral bevacizumab (Avastin®) in the management of neovascular glaucoma surgery].
abstract: OBJECTIVE
  To describe a case series of neovascular glaucoma treated with intracameral bevacizumab prior to filtering surgery.
  
  
  METHODS
  Descriptive, retrospective case series.
  
  
  METHODS
  Five eyes of 5 patients with neovascular glaucoma due to any cause candidates to filtering surgery who had previously received an injection of intracameral bevacizumab (1.25 mg/0.05 ml) as treatment for neovascularization of anterior chamber. Results observed one week and 4 weeks postsurgery are reported.
  
  
  RESULTS
  Bevacizumab produced regression of the angle neovascularization and the intraocular pressure. Only one case of postoperative bleeding was detected.
  
  
  CONCLUSIONS
  Intracameral bevacizumab prior to filtering surgery of neovascular glaucoma diminished the neovascularization and intraocular pressure after 4 weeks of its administration and was effective in preventing intraoperative and postoperative bleeding. It also constitutes a promising way of investigation to prevent surgical complications.
authors.affiliation: Servicio de Oftalmología, Hospital Universitario de Fuenlabrada, Madrid, España. hector_fernan@hotmail.com
authors.forename: H
authors.initials: H
authors.lastname: Fernández Jiménez-Ortiz
authors.forename: S
authors.initials: S
authors.lastname: Perucho Martinez
authors.forename: N
authors.initials: N
authors.lastname: Toledano Fernández
authors.forename: E
authors.initials: E
authors.lastname: Martin Giral
mesh_terms: D000328:Adult; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000627:therapeutic use; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000601:surgery; D004341:Drug Evaluation; D005260:Female; D018463:Filtering Surgery; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D056965:Injections, Intraocular; D007429:Intraocular Pressure / Q000187:drug effects; D008028:Light Coagulation; D008297:Male; D008875:Middle Aged; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D012166:Retinal Hemorrhage / Q000517:prevention & control; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab